Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
16.86
-0.91 (-5.12%)
At close: Jan 14, 2025, 4:00 PM
16.80
-0.06 (-0.36%)
After-hours: Jan 14, 2025, 5:10 PM EST
Viridian Therapeutics Revenue
Viridian Therapeutics had revenue of $86.00K in the quarter ending September 30, 2024, with 19.44% growth. This brings the company's revenue in the last twelve months to $302.00K, down -12.97% year-over-year. In the year 2023, Viridian Therapeutics had annual revenue of $314.00K, down -82.28%.
Revenue (ttm)
$302.00K
Revenue Growth
-12.97%
P/S Ratio
n/a
Revenue / Employee
$3,213
Employees
94
Market Cap
1.34B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 314.00K | -1.46M | -82.28% |
Dec 31, 2022 | 1.77M | -1.19M | -40.20% |
Dec 31, 2021 | 2.96M | 1.91M | 182.19% |
Dec 31, 2020 | 1.05M | -3.41M | -76.46% |
Dec 31, 2019 | 4.46M | -3.92M | -46.80% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
VRDN News
- 6 days ago - Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Business Wire
- 26 days ago - Viridian: Positive Chronic TED Data Likely To Lead To BLA Filing In Second Half Of 2025 (Rating Upgrade) - Seeking Alpha
- 27 days ago - Viridian Therapeutics: Veligrotug De-Risked In TED With Hints Of Differentiation - Seeking Alpha
- 4 weeks ago - Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade) - Seeking Alpha
- 4 weeks ago - Viridian Therapeutics' eye disorder drug meets late-stage study goal - Reuters
- 4 weeks ago - Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Business Wire
- 4 weeks ago - Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 - Business Wire
- 5 weeks ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire